MyoKardia and Fulcrum Therapeutics Collaborate

Aim to discover novel targeted therapies for the treatment of genetic cardiomyopathies.

By: Contract Pharma

Contract Pharma Staff

MyoKardia Inc., a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, and Fulcrum Therapeutics Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, have entered into a strategic collaboration and license agreement to discover, develop and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies.   Under...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters